Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.

Date publication

janvier 2018

Journal

Contrast media & molecular imaging

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRUNOTTE François , Pr FUMOLEAU Pierre , Pr DENAT Franck , Dr COLLIN Bertrand , Dr BELLAYE Pierre-Simon

Tous les auteurs :
Bellaye PS, Oudot A, Vrigneaud JM, Raguin O, Bichat F, Vaslin A, Maby-El Hajjami H, Zanna C, Vuagniaux G, Fumoleau P, Denat F, Brunotte F, Collin B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30627061

Résumé

Debio 1143, a potent orally available SMAC mimetic, targets inhibitors of apoptosis proteins (IAPs) members and is currently in clinical trials. In this study, nuclear imaging evaluated the effects of Debio 1143 on tumor cell death and metabolism in a triple-negative breast cancer (TNBC) cell line (MDA-MB-231)-based animal model.

Référence

Contrast Media Mol Imaging. 2018 ;2018:8494031